Moleculin Biotech (MBRX) announced that the Australian Patent Office has granted Patent No. 2024203598 titled, “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE,” with claims covering certain preliposomal Annamycin lyophilizates with improved stability and high purity, with a base patent term currently extending until June 2040, subject to extension to account for time required to fulfill requirements for regulatory approval. This patent further expands the Company’s intellectual property portfolio globally.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Moleculin Biotech’s Promising AML Study: A Closer Look
- Promising Developments in Moleculin Biotech’s Annamycin Drive Buy Rating
- Moleculin Biotech’s Promising Drug Pipeline and Strategic Expansion Justify Buy Rating
- Moleculin Biotech Partners with Atlantic Health System
- Moleculin Biotech works with Atlantic Health on Phase 1B/2 study of Annamycin